Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit

EW

LOS ANGELES, Oct. 24, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW).

(PRNewsfoto/The Law Offices of Frank R. Cru)

Class Period: February 6, 2024July 24, 2024
Lead Plaintiff Deadline:December 13, 2024

If you are a shareholder who suffered a loss, click here to participate.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) the Company did not possess reliable information pertaining to projected revenue outlook and anticipated growth; (2) the Company's growth was at risk of decelerating; (3) the Company's "patient activation activities" failed to reach the perceived low-treatment-rate population TAVR's growth relied upon obtaining; (4) the Company overstated hospital desire to continue to utilize the Company's TAVR procedures over newer, innovative structural heart therapies; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ew-investors-have-opportunity-to-lead-edwards-lifesciences-corporation-securities-fraud-lawsuit-302286646.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today